Product
Tolinapant
Aliases
ASTX660, XIAP/cIAP1 Antagonist ASTX660
4 clinical trials
30 indications
Indication
Head and Neck Squamous Cell CarcinomaIndication
Hypopharyngeal Squamous Cell CarcinomaIndication
Laryngeal Squamous Cell CarcinomaIndication
Nasopharyngeal Squamous Cell CarcinomaIndication
Oropharyngeal CancerIndication
Rectal CancerIndication
Fallopian Tube CarcinomaIndication
Platinum-Refractory Ovarian CarcinomaIndication
Primary Peritoneal CarcinomaIndication
Recurrent Fallopian Tube AdenocarcinomaIndication
Recurrent fallopian tube carcinosarcomaIndication
Clear Cell AdenocarcinomaIndication
High-Grade Serous AdenocarcinomaIndication
Endometrioid AdenocarcinomaIndication
Recurrent Ovarian AdenocarcinomaIndication
Recurrent Ovarian CarcinosarcomaIndication
Ovarian Clear Cell AdenocarcinomaIndication
Ovarian High Grade Serous AdenocarcinomaIndication
Recurrent Ovarian Seromucinous CarcinomaIndication
Ovarian CancerIndication
Platinum-Resistant Ovarian CarcinomaIndication
Peritoneal AdenocarcinomaIndication
Primary Peritoneal CarcinosarcomaClinical trial
Early-Phase Open-label Study of Tolinapant and Radiation in Cisplatin-Ineligible Patients With Previously Untreated, Locally Advanced Head and Neck CancerStatus: Recruiting, Estimated PCD: 2025-10-21
Clinical trial
A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2028-02-09